To **BSE Limited** 1st Floor, P.J. Towers Dalal Street Mumbai – 400 001 **Code: 532321**	To **The National Stock Exchange of India Limited** Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) Mumbai – 400 051 **Symbol: CADILAHC**
Date: November 04, 2019	
Reg.: Warning Letter – US FDA	

Dear Sir / Madam,

We hereby inform that the Company has received a Warning Letter issued by the US FDA relating to its Moraiya formulation facility.

The Company has taken multiple steps after the inspection to address the observations received from US FDA during the inspection. The Company will continue to take all necessary steps to ensure that the US FDA is fully satisfied with our remediation of the above facility. We are confident of responding to US FDA to address the observations within the statutory time permitted in the letter.

This warning letter does not affect the existing business of the company in the US and the existing product supplies from the Moraiya facility will continue.

Zydus remains committed to patient safety and meeting the expectations of regulatory compliances. After the inspection of Moraiya facility, Zydus Cadila has successfully completed

USFDA audits of formulations manufacturing facility at Baddi, and API manufacturing facilities at Ankleshwar and Dabhasa during the year.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,
FOR **CADILA HEALTHCARE LIMITED**

Dhaval Soni
COMPANY SECRETARY